Novo at 24% Upside Looks Undervalued-If the Obesity Panic Is Overdone

The selloff reflects broken confidence, not a final verdict on Novo's obesity franchise

Investors appear to have reacted with panic rather than measured recalibration. Novo has seen stock fall 17% in the last 30 days, while the company still carries a 75% drawdown from its mid-2024 peak. The real shock came from management guiding to a 5% to 13% 2026 sales decline at a time when expectations were far more benign.

The trigger was easy to identify. Novo's latest CagriSema late-stage data underperformed Lilly's Zepbound, and the comparative design made Zepbound look stronger than some of Lilly's own prior readings. In a market anchored to the idea that Novo should steer the obesity hierarchy, that kind of setback can spread quickly.

Still, there is a difference between a damaged narrative and a vanished moat. Reuters also reported Novo's shares tanked 16% after the data, underscoring how fast sentiment can unwind when investors lose faith in the category leader. The current debate is whether Novo is losing ground in a harder market or losing the franchise altogether.

Pricing pressure, not demand collapse, is the central operating issue

Guidance improved slightly as the pricing reset became clearer

Novo's outlook has softened, but it has also become more transparent. Management now expects 4% to 12% contraction in adjusted 2026 sales and profit, an upgrade from the earlier 5% to 13% sales decline. The key driver is still pricing: U.S. price reductions will drive a sales contraction even if volumes keep growing.

That matters because reported figures can mask the split between price and volume. In the first quarter, first-quarter sales jumped 32% on a constant currency basis, but adjusted sales still fell. The better read is that demand has not disappeared; revenue capture has simply come under pressure.

Volume signals still argue against a full narrative break

The clearest check on the bearish case is not a distant pipeline promise but current commercial traction. Novo says Wegovy brand now has 65% of all new prescriptions in the U.S., and Reuters noted the company is banking on fast-rising volumes can offset a bruising obesity drug price war. That is not the profile of a business with no pull. It looks more like a business with real demand and weaker unit economics than investors were used to.

Competition and pipeline setbacks have weakened the story, even if they do not end it

Once pricing pressure became the dominant lens, every new setback carried more weight. Novo's next-generation weight-loss drug didn't meet its key goal, which gave critics fresh evidence of pipeline underperformance. Reuters also described the event as disappointing outcome in Novo's effort to reclaim ground from Lilly.

At the same time, the comparison frame is hard to ignore. Lilly's cardiometabolic business produced nearly $40 billion in 2025 cardiometabolic revenues, reinforcing the view that Lilly is executing well across a broader franchise. That does not mean Novo's moat is gone. It does mean the market has less tolerance for mistakes.

What could close the gap between Novo's price and its value

Proof points that could support a rerating

• Management has already nudged expectations higher, now forecasting 4% to 12% contraction versus the prior 5% to 13% sales decline.
• Demand evidence is still visible, with Wegovy reportedly capturing 65% of all new prescriptions in the U.S..
• The quarter still showed operating resilience, with adjusted operating profit above expectations.
• Revenue can still grow strongly when pricing is less of a drag, as shown by first-quarter sales jumped 32% on a constant currency basis.

Signals that would break the undervalued view

• If management can no longer separate price softness from demand weakness, the market is likely to treat pricing pressure, fierce competition, and pipeline setbacks as a structural problem rather than a reset.
• If future obesity data again didn't meet its key goal, investors may stop viewing setbacks as temporary friction.
• If Lilly continues to look like the faster, broader winner-with nearly $40 billion in 2025 cardiometabolic revenues-Novo's confidence discount could persist even if the business remains large and profitable.

That is why this is as much a timing call as a valuation call. If upcoming updates show stable volumes and only gradual improvement against the guided contraction, the stock could rerate before the bearish narrative fully stabilizes. After a 17% drop in the last 30 days, sentiment looks unusually fragile.